Is QDEL or VRAX more undervalued in 2026?

CirclFi compares QuidelOrtho Corporation (QDEL) and Virax Biolabs Group Limited (VRAX) using 13 institutional-grade valuation models. QDEL has a Quality of Company score of 5.8/10 while VRAX scores 1.6/10.

Which is a better buy — QDEL or VRAX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do QDEL and VRAX valuations compare?

QDEL at $13.02 and VRAX at $0.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

QDEL vs VRAX Valuation Comparison 2026 — Intrinsic Value Analysis

QDEL

In Vitro & In Vivo Diagnostic Substances

QuidelOrtho Corporation

Quality

5.8

out of 10

Value Trap

WARN

Price

$13.02

Last close

Models

9/13

Active

VRAX

In Vitro & In Vivo Diagnostic Substances

Virax Biolabs Group Limited

Quality

1.6

out of 10

Value Trap

SAFE

Price

$0.19

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	QDEL Fair Value	QDEL Upside	VRAX Fair Value	VRAX Upside
Bayesian DCF	Intrinsic	$58.63	+350.3%	$0.04	-79.1%
Earnings Power Value	Intrinsic	$18.64	+47.5%	—	—
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$41.84	+221.4%	$0.28	+125.8%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for QDEL vs VRAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

QDEL vs VRAX — Which Stock Is More Undervalued?

QDEL scores higher with a 5.8/10 quality rating vs VRAX's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing QuidelOrtho Corporation (QDEL) and Virax Biolabs Group Limited (VRAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

QDEL currently trades at $13.02 with a QOC of 5.8/10, while VRAX trades at $0.19 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).